Short-term stake in Nyxoah SA (NASDAQ:NYXH) decreases by 20.0%
Nyxoah SA (NASDAQ:NYXH – Get Rating) benefited from a significant decline in short-term interest in October. As of October 15, there was short interest totaling 400 shares, down 20.0% from the total of 500 shares as of September 30. Based on an average trading volume of 3,500 shares, the day-to-cover ratio is currently 0.1 day.
Nyxoah Institutional Trade
Several institutional investors have recently changed their stock portfolios. Optiver Holding BV acquired a new stake in Nyxoah during the 2nd quarter for a value of $35,000. Banque Cantonale Vaudoise increased its stake in Nyxoah shares by 150.0% in the third quarter. Banque Cantonale Vaudoise now owns 30,000 shares of the company valued at $194,000 after buying an additional 18,000 shares in the last quarter. Sei Investments Co. acquired a new equity stake in Nyxoah in Q2 valued at approximately $265,000. DekaBank Deutsche Girozentrale bought a new position in Nyxoah during Q2 worth around $353,000. Finally, Invesco Ltd. bought a new position in Nyxoah during Q1 worth approximately $8,177,000. Hedge funds and other institutional investors hold 12.07% of the company’s shares.
Analyst upgrades and downgrades
Separately, Piper Sandler cut her price target on Nyxoah shares from $30.00 to $20.00 and set an “overweight” rating for the company in a Tuesday, Aug. 9 research note.
Nyxoah Price Performance
The NASDAQ NYXH traded down $0.13 during Friday’s session, hitting $6.03. 303 shares of the company were traded, against an average volume of 5,447. The company has a 50-day moving average price of $6.99 and a two-hundred-day moving average price of $10.57. Nyxoah has a 1-year low of $5.36 and a 1-year high of $29.28. The company has a quick ratio of 7.21, a current ratio of 7.24 and a leverage ratio of 0.08.
Nyxoah (NASDAQ:NYXH – Get Rating) last released its results on Monday August 8th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.11. The company posted revenue of $1.00 million for the quarter, versus analyst estimates of $1.04 million. Sell-side analysts expect Nyxoah to post -1.13 EPS for the current fiscal year.
Nyxoah Company Profile
(Get an evaluation)
Nyxoah SA, a medical technology company, is focused on developing and commercializing solutions to treat sleep-disordered breathing. It offers the Genio System, a hypoglossal, patient-centered, CE-marked neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Nyxoah, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Nyxoah didn’t make the list.
Although Nyxoah currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here